Multicenter phase II trial of brequinar sodium in patients with advanced squamous-cell carcinoma of the head and neck
- 1 January 1992
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 31 (2), 167-169
- https://doi.org/10.1007/bf00685106
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignanciesCancer Chemotherapy and Pharmacology, 1990
- Phase I and pharmacokinetic study of brequinar sodium (NSC 368390).1990
- A phase I clinical and pharmacokinetic study of brequinar sodium, DUP 785 (NSC 368390), using a weekly and a biweekly scheduleEuropean Journal of Cancer and Clinical Oncology, 1989
- Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).1989
- Mucocutaneous side effects of brequinar sodium. A new inhibitor of pyrimidine de novo biosynthesisCancer, 1989
- DUP 785 (NSC 368390): Schedule-dependency of growth-inhibitory and antipyrimidine effectsBiochemical Pharmacology, 1988
- Mechanism of action of the novel anticancer agent 6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarbo xylic acid sodium salt (NSC 368390): inhibition of de novo pyrimidine nucleotide biosynthesis.1986
- Activity of a novel 4-quinolinecarboxylic acid, NSC 368390 [6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarb oxylic acid sodium salt], against experimental tumors.1985